S

Shanghai Henlius Biotech
2696

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
HK$43.02B
EV
HK$45.97B
Shares Outstanding
543.49M
Beta
0.76

Wall Street View

Analyst Rating
BUY
Analyst Target Price
HK$77.37
P/E 2025E
45.80x
P/Revenue 2025E
6.63x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Shanghai Henlius Biotech, Inc.

gainify

S

Shanghai Henlius Biotech, Inc.

2696

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leuke...

Sector

Healthcare

Industry

Biotechnology

CEO

Zhu, Jun

Employees

3,515

IPO Date

2019-09-25

Headquarters

Building B8, 11th Floor, 188 Yizhou Road, Xuhui District, Shanghai 200233, China

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.